Common Stock, par value $0.0001 per share

IMMUNOME, INC.

18702 North Creek Parkway, Bothell, WA, 98011

This Schedule 13D is filed by Enavate Sciences GP, LLC ("Enavate GP") and Immunome Aggregator, LP (with Enavate GP, collectively, the "Reporting Entities"). The Reporting Entities expressly disclaim status as a "group" for purposes of this Schedule 13D.

The principal business office of Enavate GP is 2882 Sand Hill Road, Suite 100, Menlo Park, CA 94025. The principal business office of Immunome Aggregator, LP is 106 W 56th Street, 8th Floor, New York, NY 10019.

The principal business of Enavate GP is performing the functions of, and serving as, the sole general partner of Immunome Aggregator, LP and certain affiliated partnerships, which make venture capital investments. The principal business of Immunome Aggregator, LP is investing in and holding the securities of the Issuer.

During the last five years, none of the Reporting Entities has been a party to a civil proceeding of a judicial of administrative body of competent jurisdiction or were subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

Each of Enavate GP and Immunome Aggregator, LP was organized in the state of Delaware.

Rows 11 and 13 of each Reporting Entities' cover page to this Schedule 13D set forth the aggregate number of shares of Common Stock and percentages of the shares of Common Stock beneficially owned by such Reporting Entity and are incorporated by reference. The percentage set forth in each row 13 is based upon 79,776,901 shares of common stock outstanding as of January 31, 2024 as disclosed in the Issuer's prospectus supplement dated January 29, 2025 filed with the SEC on January 30, 2025.

Rows 7 through 10 of each Reporting Entities' cover page to this Schedule 13D set forth the number of shares of Common Stock as to which such Reporting Entity has the sole or shared power to vote or direct the vote and sole or shared power to dispose or to direct the disposition and are incorporated by reference.

Except as set forth herein, none of the Reporting Entities has effected any transactions with respect to the securities of the Issuer during the past sixty days.

No other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of the Common Stock.

Not applicable.